[go: up one dir, main page]

CY1118956T1 - Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης - Google Patents

Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης

Info

Publication number
CY1118956T1
CY1118956T1 CY20171100439T CY171100439T CY1118956T1 CY 1118956 T1 CY1118956 T1 CY 1118956T1 CY 20171100439 T CY20171100439 T CY 20171100439T CY 171100439 T CY171100439 T CY 171100439T CY 1118956 T1 CY1118956 T1 CY 1118956T1
Authority
CY
Cyprus
Prior art keywords
disease
alzheimer
treatment
relates
therapeutic
Prior art date
Application number
CY20171100439T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Oxana Guerassimenko
Esther Graudens
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of CY1118956T1 publication Critical patent/CY1118956T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε συνθέσεις και μεθόδους για τη θεραπεία της νόσου Alzheimer και των συγγενών διαταραχών. Ειδικότερα, η εφεύρεση αφορά σε συνδυασμένες θεραπείες που διαμορφώνουν την αγγειογένεση για τη θεραπευτική αντιμετώπιση της εν λόγω νόσου. Σε μια προτιμώμενη ενσωμάτωση, η εφεύρεση αναφέρεται σε μια σύνθεση που περιλαμβάνει έναν συνδυασμό τουλάχιστον δύο ενώσεων που επιλέγονται από την ομάδα που αποτελείται από λεφλουνομίδη, σουλφισοξαζόλη, τερβιναφίνη, μπακλοφέν, κλοπιδογρέλη, τενολδοπάμη, μεπακρίνη και φαινολδοπάμη ή τα άλατα ή τα προφάρμακα ή τα παράγωγα ή τα σκευάσματα τους συνεχούς αποδέσμευσης, για ταυτόχρονη, χωριστή ή διαδοχική χορήγηση.
CY20171100439T 2008-04-29 2017-04-13 Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης CY1118956T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4858308P 2008-04-29 2008-04-29
PCT/EP2009/055205 WO2009133141A2 (en) 2008-04-29 2009-04-29 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis

Publications (1)

Publication Number Publication Date
CY1118956T1 true CY1118956T1 (el) 2018-01-10

Family

ID=41222690

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100439T CY1118956T1 (el) 2008-04-29 2017-04-13 Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης

Country Status (23)

Country Link
US (1) US11291670B2 (el)
EP (1) EP2282778B1 (el)
JP (1) JP5721230B2 (el)
KR (1) KR101660401B1 (el)
CN (1) CN102065898B (el)
AU (1) AU2009242126B2 (el)
BR (1) BRPI0911520A2 (el)
CA (1) CA2722453C (el)
CY (1) CY1118956T1 (el)
DK (1) DK2282778T3 (el)
EA (1) EA021731B1 (el)
ES (1) ES2622504T3 (el)
HR (1) HRP20170531T1 (el)
HU (1) HUE033726T2 (el)
IL (1) IL208982B (el)
LT (1) LT2282778T (el)
MX (1) MX2010011881A (el)
NZ (1) NZ589307A (el)
PL (1) PL2282778T3 (el)
PT (1) PT2282778T (el)
SI (1) SI2282778T1 (el)
WO (1) WO2009133141A2 (el)
ZA (1) ZA201008037B (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP2285374B1 (en) * 2008-04-29 2019-09-18 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP3357495B1 (en) 2008-11-19 2019-12-25 Axovant Sciences GmbH Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP3272748B1 (en) 2010-05-17 2019-06-19 Forum Pharmaceuticals Inc. Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
US8957098B2 (en) 2010-08-24 2015-02-17 Algiax Pharmaceuticals Gmbh Use of leflunomide and malononitrilamides
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
US8980261B2 (en) * 2011-02-11 2015-03-17 The Rockefeller University Treatment of angiogenesis disorders
EP2727588B1 (en) * 2011-03-01 2018-08-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
JP6430445B2 (ja) * 2011-03-01 2018-11-28 ファーネクストＰｈａｒｎｅｘｔ バクロフェンおよびアカンプロセートに基づく神経疾患の治療
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
RS56175B1 (sr) * 2012-03-01 2017-11-30 Pharnext Nove kompozicije za lečenje amiotrofične lateralne skleroze
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR101579008B1 (ko) * 2013-09-25 2015-12-22 경북대학교 산학협력단 ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2938361A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
CN104928353A (zh) * 2014-03-19 2015-09-23 上海吉凯基因化学技术有限公司 人dgkz基因的用途及其相关药物
WO2016054083A1 (en) * 2014-09-30 2016-04-07 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis
WO2016201086A1 (en) * 2015-06-12 2016-12-15 Rush University Medical Center Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein
JP7027318B2 (ja) * 2016-02-05 2022-03-01 ファーネクスト 神経障害の新規の併用療法
EP3544604A4 (en) 2016-11-23 2020-07-22 Ramot at Tel-Aviv University Ltd. METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATING TO CORTICO-HIPPOCAMPAL HYPERACTIVITY
AU2018258970B2 (en) 2017-04-24 2021-07-15 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
US11382897B2 (en) 2017-11-07 2022-07-12 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
CN111084768A (zh) * 2018-10-24 2020-05-01 中国科学院昆明动物研究所 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途
WO2020111171A1 (ja) * 2018-11-29 2020-06-04 雪印メグミルク株式会社 血管新生促進用組成物
CN110806488B (zh) * 2019-12-06 2020-09-25 南京医科大学 Drd5及其激动剂在制备治疗炎症性疾病的药物中的应用
JP2023521646A (ja) * 2020-03-31 2023-05-25 ウィルフレッド ジェフリーズ アルツハイマー病の治療方法
WO2023059867A1 (en) * 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072688A (ja) * 1991-06-11 1995-01-06 Rikomu:Kk 腸内有毒腐敗産物抑制剤
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders

Also Published As

Publication number Publication date
ZA201008037B (en) 2011-08-31
PL2282778T3 (pl) 2017-08-31
WO2009133141A2 (en) 2009-11-05
EA201071244A1 (ru) 2011-06-30
EP2282778B1 (en) 2017-03-08
WO2009133141A3 (en) 2009-12-30
US11291670B2 (en) 2022-04-05
CN102065898A (zh) 2011-05-18
MX2010011881A (es) 2011-07-01
KR20110010734A (ko) 2011-02-07
CN102065898B (zh) 2015-08-26
LT2282778T (lt) 2017-06-26
KR101660401B1 (ko) 2016-09-27
BRPI0911520A2 (pt) 2017-06-13
ES2622504T3 (es) 2017-07-06
CA2722453A1 (en) 2009-11-05
HUE033726T2 (en) 2017-12-28
IL208982A0 (en) 2011-01-31
AU2009242126B2 (en) 2014-03-27
US20120058992A1 (en) 2012-03-08
CA2722453C (en) 2018-03-20
HRP20170531T1 (hr) 2017-06-16
PT2282778T (pt) 2017-04-27
IL208982B (en) 2018-03-29
JP5721230B2 (ja) 2015-05-20
EP2282778A2 (en) 2011-02-16
EA021731B1 (ru) 2015-08-31
DK2282778T3 (en) 2017-05-01
SI2282778T1 (sl) 2017-07-31
JP2011518864A (ja) 2011-06-30
AU2009242126A1 (en) 2009-11-05
NZ589307A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CY1118956T1 (el) Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
MX2020007479A (es) Profármacos de ketamina, composiciones y usos de los mismos.
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
CO6501155A2 (es) Compuestos derivados de amina para tratar enfermedades y transtornos oftalmicos
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EA201001639A1 (ru) Композиции и способы их получения и применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
BR112014015923A8 (pt) formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4-acetilaminoisoindolina-1,3-diona
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.